Janus Henderson Group Portfolio holdings
Janus Henderson Group, formed in 2017 through the merger of Janus Capital Group (founded 1969) and Henderson Group (founded 1934), is a global asset management firm headquartered in London, managing over $350 billion in assets as of late 2024 for institutional, retail, and high-net-worth clients. With a strong presence in the U.S., Europe, and Asia-Pacific, the firm offers a wide range of investment products, including equities, fixed income, multi-asset, and alternative strategies, often blending active management with research-driven insights. Known for its equity expertise from Janus’s growth-focused heritage and Henderson’s European fixed-income strengths, Janus Henderson serves clients through mutual funds, ETFs, and bespoke portfolios, emphasizing risk-adjusted returns and ESG integration. Led by CEO Ali Dibadj since 2022, the publicly traded firm (NYSE: JHG) continues to refine its strategy amid competitive pressures, maintaining a foothold in key markets worldwide.
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
Linde
LIN
|
+$554M |
| 2 |
Apple
AAPL
|
+$513M |
| 3 |
Illumina
ILMN
|
+$360M |
| 4 |
argenx
ARGX
|
+$304M |
| 5 |
CTLT
CATALENT, INC.
CTLT
|
+$235M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
Meta Platforms (Facebook)
META
|
+$482M |
| 2 |
Sherwin-Williams
SHW
|
+$314M |
| 3 |
AbbVie
ABBV
|
+$310M |
| 4 |
HZNP
Horizon Therapeutics Public Limited Company Ordinary Shares
HZNP
|
+$244M |
| 5 |
Atlassian
TEAM
|
+$233M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Technology | 31.85% |
| 2 | Healthcare | 19.69% |
| 3 | Industrials | 10.47% |
| 4 | Financials | 10.02% |
| 5 | Consumer Discretionary | 9.96% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
2601
Nurix Therapeutics
NRIX
$2.7B
| $115K | ﹤0.01% |
+12,954
| New | +$135K |
|
2602
Scholar Rock
SRRK
$6.35B
| $115K | ﹤0.01% |
+14,286
| New | +$145K |
|
2603
MiMedx Group
MDXG
$630M
| $114K | ﹤0.01% |
33,649
+18,874
| +128% | +$73.1K |
|
2604
Unisys
UIS
$209M
| $113K | ﹤0.01% |
29,089
+16,266
| +127% | +$78.6K |
|
|
SRG
2605
Seritage Growth Properties
SRG
$136M
| $113K | ﹤0.01% |
+14,308
| New | +$159K |
|
2606
Tredegar Corp
TG
$282M
| $111K | ﹤0.01% |
+12,163
| New | +$135K |
|
2607
AtaiBeckley Inc
ATAI
$2.68B
| $110K | ﹤0.01% |
61,508
+29,569
| +93% | +$50.1K |
|
2608
ImmunityBio
IBRX
$8.04B
| $109K | ﹤0.01% |
60,325
+28,703
| +91% | +$89.2K |
|
2609
Radiant Logistics
RLGT
$386M
| $109K | ﹤0.01% |
16,565
-1,662
| -9% | -$9.29K |
|
2610
Codexis
CDXS
$160M
| $105K | ﹤0.01% |
25,507
+13,703
| +116% | +$71.9K |
|
2611
Altimmune
ALT
$587M
| $101K | ﹤0.01% |
23,986
-3,809,593
| -99% | -$45.3M |
|
|
SGMO
2612
DELISTED
SANGAMO THERAPEUTICS INC
SGMO
| $99.7K | ﹤0.01% |
56,831
+32,100
| +130% | +$91.6K |
|
|
PSTX
2613
DELISTED
Poseida Therapeutics, Inc. Common Stock
PSTX
| $99.7K | ﹤0.01% |
+32,317
| New | +$194K |
|
2614
Sana Biotechnology
SANA
$1.01B
| $98.8K | ﹤0.01% |
30,247
+20,172
| +200% | +$80.6K |
|
2615
Clarus
CLAR
$147M
| $96.6K | ﹤0.01% |
+10,231
| New | +$96.1K |
|
2616
Atara Biotherapeutics
ATRA
$80.1M
| $95K | ﹤0.01% |
1,313
+731
| +126% | +$70.9K |
|
2617
Hyliion Holdings
HYLN
$720M
| $94.7K | ﹤0.01% |
47,956
+28,736
| +150% | +$80K |
|
2618
FuboTV Inc
FUBO
$286M
| $93.1K | ﹤0.01% |
6,437
+3,422
| +113% | +$78.2K |
|
2619
Vuzix
VUZI
$223M
| $92.9K | ﹤0.01% |
+22,578
| New | +$102K |
|
|
TVRD
2620
Tvardi Therapeutics
TVRD
$22.5M
| $92.8K | ﹤0.01% |
+526
| New | +$176K |
|
2621
BrightView Holdings
BV
$1.05B
| $92K | ﹤0.01% |
+16,391
| New | +$111K |
|
2622
Butterfly Network
BFLY
$2.52B
| $91.5K | ﹤0.01% |
48,543
+28,268
| +139% | +$66K |
|
2623
Ranpak Holdings
PACK
$460M
| $87.3K | ﹤0.01% |
+16,758
| New | +$106K |
|
2624
Kodiak Sciences
KOD
$2.62B
| $87.2K | ﹤0.01% |
+14,037
| New | +$98.2K |
|
2625
Workhorse Group
WKHS
$33.6M
| $84.8K | ﹤0.01% |
21
+14
| +200% | +$77.3K |
|
Similar funds
Janus Henderson Group's Q1 2023 Portfolio in Review
As of Q1 2023, Janus Henderson Group held 2,845 positions worth $152B, up 8.3% from $140B the previous quarter. Its ten largest holdings account for 24% of the portfolio.
Janus Henderson Group's Q1 2023 filing shows 389 new, 1,670 increased, 578 reduced and 160 closed positions. Its largest new stake was GE HealthCare: 882,749 shares worth $72.4M. The largest sale was Meta Platforms (Facebook), an estimated $482M.
By sector, the portfolio is most concentrated in Technology at 32% of assets, up from 28% a quarter earlier, followed by Healthcare and Industrials.
- Janus Henderson Group's largest Q1 2023 buy was GE HealthCare: 882,749 shares worth $72.4M.
- Janus Henderson Group added most to Linde in Q1 2023, an estimated $554M increase.
- Janus Henderson Group's biggest Q1 2023 reduction was Meta Platforms (Facebook), cutting an estimated $482M.
- Janus Henderson Group fully exited Myovant Sciences Ltd. in Q1 2023, selling an estimated $31.7M.
- Janus Henderson Group's ten largest holdings make up 24% of its $152B portfolio in Q1 2023.
- Janus Henderson Group opened 389 new positions and closed 160 in Q1 2023.
- Janus Henderson Group's portfolio value rose 8.3% quarter-over-quarter to $152B.
Based on Janus Henderson Group's 13F filing for Q1 2023, filed 15 May 2023.